Researchers have found in a phase 1 nonrandomized clinical trial that autologous umbilical cord blood cells (UCBCs) were safe and feasible in extremely preterm infants, with no significant differences in brain imaging or early neurodevelopmental outcomes compared to untreated controls. Notably, none of the UCBC-treated infants were assessed as high risk for cerebral palsy at 52–54 weeks postmenstrual age, warranting further investigation.

Umbilical cord blood–derived cells (UCBCs) are increasingly being evaluated for neuroprotective properties in perinatal brain injury.

A study was done to report early neurodevelopmental outcomes of extremely preterm infants who received autologous UCBCs in the CORD-SaFe study. This study reports early follow-up on the preplanned secondary aims of a phas

See Full Page